• Product
• Unsure efficacy of Alzheimer's drug aducanumab
• by Choi-sun May 10, 2022 06:07am

• Product
• Aftermath of Revlimid of primary benefit multiple myeloma
• by Whang, byung-woo Apr 28, 2022 06:06am

• Product
• The KPA establishes an emergency TFT
• by Apr 20, 2022 06:05am

• Product
• Non-face-to-face tx companies are appealing for regulations
• by Jung, Heung-Jun Apr 20, 2022 06:05am

• Product
• Immunity products fare better “targeting the long COVID mkt
• by Apr 19, 2022 05:52am

• Product
• Gov discusses presenting regulatory sandboxes for ER OTC
• by Jung, Heung-Jun Apr 18, 2022 05:57am

• Product
• Lagevrio prescriptions exceed 2,000… Paxlovid's up 25.6%
• by Kang, Shin-Kook Apr 5, 2022 05:58am

• Product
• Only Paxlovid's prescription continues instead of Lagevrio
• by Jung, Heung-Jun Mar 29, 2022 05:54am

• Product
• Butterfly effect caused by brand name purchase
• by Kim JiEun Mar 23, 2022 05:50am

• Product
• Paxlovid shortage to be resolved with Molnupiravir approval?
• by Jung, Heung-Jun Mar 21, 2022 05:55am